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1. Introduction 
It has been more than ten years since the first Human Leukocyte Antigen (HLA) matching 
for Fanconi anemia was reported, allowing successful haemopoietic reconstitution in 
affected sibling by transplantation of stem cells obtained from HLA-matched offspring 
(Verlinsky et al., 2000; Verlinsky et al., 2001). Preimplantation Genetic Diagnosis (PGD) in 
combination with HLA matching is being used to detect a particular gene mutation in an 
unaffected child who can be an HLA donor for its’ sibling. HLA typing without mutation 
analysis has also been used for acquired diseases (Verlinsky et al., 2004), such as acute 
myeloid leukemia (AML) and acute lymphoid leukemia (ALL), which require allogenic 
haemopoietic stem cell transplantation (HSCT) from an HLA identical donor for the cure of 
the disease. Stem cells in the cord blood from an HLA identical sibling can be used with a 
much higher success rate than a transplant from alternative donors (Gaziev et al., 2000; 
Orofino et al., 2003) and are therefore of great therapeutic value for hematopoietic and other 
life-threatening diseases (Fiorentino et al., 2006; Kahraman et al., 2004, 2007; Verlinsky et al., 
2001, 2004; Van de Velde et al., 2004, 2009).  
In particular for blood-borne disorders, hematopoietic stem cells (HSC) from HLA-identical 
siblings provide the highest success rate and current results indicate that about 90% of the 
cases can be cured successfully after HSC transplantation (Gaziev et al., 2005). Use of cord 
blood as a stem cell source also results in reduced incidence of graft rejection and other 
serious complications associated with bone marrow transplantation. However, in most cases 
a suitable donor cannot be found in the family, and due to a small number of children per 
family, only one third of patients are able to find an HLA-identical sibling (Costeas, 2004). 
The probability of having an unaffected child who may also be an HLA match for an 
affected sibling is only one in five; these families often went through multiple cycles of 
pregnancy before conceiving an unaffected HLA match. In the remaining patients the only 
resort is the identification of a matched unrelated donor. However, the probability of 
finding an HLA matched unrelated donor cord blood from the cord blood units is extremely 
low. Therefore PGD is a much more attractive option, with this technique, sufficient number 
of embryos may be tested at one time, increasing the chances of identifying an appropriate 
match.  
More than 2000 healthy children have already been born after PGD and the expanding 
indications include chromosomal abnormalities, single gene disorders, HLA tissue typing of 
the embryos, predisposition of adult onset disorders, translocations and cancer 
predispositions (Simpson 2001; Kuliev et al., 2004; Fiorentino et al., 2004; 2006; Kahraman et 
al., 2005; 2007; Van de Velde et al., 2004; Kokkali et al., 2007). In fact PGD can be carried out 
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for any disorder in which molecular testing can be performed. A partial list of disorders in 
which Preimplantation Genetic Diagnosis/HLA typing can be applied is shown in Table 1.  
Although the majority of these disorders are due to rare genetic defects, the incidence of 
some, such as β thalassemia, sickle cell anemia and cystic fibrosis are very common in 
certain parts of the world, such as Mediterranean region which include Turkey, Italy, Greece 
and Cyprus. Turkey is one of the Mediterranean countries in which thalassemia mutations 
are commonly seen, with a carrier rate of 2.1% in the population (Aksoy, et al., 1985).  
 
Achondroplasia (FGFR3) Hyper IgM  
Acute Lymphocytic Leukemia (ALL) Krabbe (GALC) 
Acute Myelogenous Leukemia (AML) Li-Fraumeni Syndrome (TP53) 
Alpha-Thalassemia (HBA) Marfan Syndrome (MFN1) 
Alzheimer Early Onset (PSEN1) Metachromatic Leukodystrophy (ARSA) 
Beta-Thalassemia (HBB) Mucolipidosis 2 (I-Cell) 
Charcot-Marie-Tooth  Myotonic Dystrophy  
Chronic Granulamatous Disease (CYBB) Neurofibromatosis (NF1 &NF2) 
Chronic Myelogenous Leukemia (CML) Neiman Pick Type C 
Crigler Najjar (UGTIA1) Phenylketanuria (PKU) 
Cystic Fibrosis (CFTR) Polycystic Kidney Disease (AR-PKD1) 
Diamond Blackfan Anemia( DBA-RSP19) Retinoblastoma  
Duchenne Muscular Distrophy (DMD) Sanflippo A (MPSIIIA) 
Fanconi Anemia A,C,F,G 
Severe combined immunodeficiency (SCID-
XI) 
Fragile X (FMR1) Sickle Cell (HBB) 
Gaucher Disease (GBA) Spinal Muscular Atrophy (SMN1) 
Glycogen Storage Disease,type IA Spinocerebellar Ataxia (SCA-2,SCA-3) 
Hemophilia A,B Tay Sacs (HEXA) 
Huntington Disease (HD) Tuberosclerosis (TSC1) 
Hurler Syndrome (MPSI-IDUA) Wiscott-Aldrich Syndome  
Table 1. Some of the current indications of PGD/HLA Typing 
According to data collected by the Turkish Association of Thalassemia, the heterozygosity 
rate may be higher than 10%, particularly in the southern regions of Turkey (Basak et al., 
2007). A higher rate of consanguineous marriages in those regions is a factor which further 
increases the incidence of thalassemia. In addition, thalassemia has a great heterogeneity in 
Turkey, the total frequency of the 6 most commonly seen mutations is only 69% of the whole 
mutations. The selection of embryos for HLA typing necessitates the application of ART 
even though the vast majority of the couples are fertile. The successful outcome of ART 
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cycles is highly dependent on female age and ovarian reserve. This technique is made 
crucially important by the fact that, the theoretical probability of finding an HLA identical 
embryo in cases of acquired diseases is 25% (1/4) and the probability of finding both HLA 
identical and mutation free embryo in cases of single gene disorders no more than 18% 
(3/16). Using a standard IVF procedure, oocytes or embryos are tested for causative gene 
mutations simultaneously with HLA alleles, selecting and transferring only those unaffected 
embryos, which are HLA matched to the affected sibling. 
The HLA Complex (Human Leukocyte Antigen) is located on chromosome 6 and represents 
one of the most polymorphic regions of human genome. Comparative DNA sequence 
analysis of HLA complex has shown the presence of a high number of alleles in this region. 
Linked short tandem repeat (STR) markers scattered through the HLA complex were 
studied to increase the accuracy of the analysis and to detect potential contaminations and 
crossing over occurrence between HLA genes.  
Single cell PCR technique has several pitfalls, such as contamination by extraneous DNA, 
amplification failure, preferential amplification, and allele drop out (ADO) which is the 
failure of PCR to amplify one of the two alleles. If ADO occurs, only a single allele is 
amplified and detected after PCR, giving a heterozygous cell the appearance of 
homozygosity. This may lead to harmful consequences such as in the case for a dominant 
disease; failure to amplify the mutant allele may lead to the transfer of affected embryos. 
The ADO rate and the efficiency of amplification of targeted regions depend on efficient 
lysis methods (Shirazi et al., 2009) and also the type of cell analyzed. With simultaneous 
usage of linked STR markers the accuracy of single cell PCR is approximately 98% 
(Rechitsky et al., 2001). ADO rates in single cells can be decreased by analyzing more than 
one cell which is possible with blastocyst-stage biopsy. Trophectoderm biopsy is a good 
alternative to cleavage stage biopsy as it enables the evaluation of approximately 2-5 cells, 
thus decreasing both the rate of amplification failures and ADO associated with single cell 
PCR (McArthur et al., 2008; Pangalos et al., 2008). There are many advantages of blastocyst 
stage biopsy such that; since trophectoderm cells are extra-embryonic tissue, the removal of 
these cells avoids the risk of affecting the development of the fetus. Also the proportion of 
the cells that are removed is much lower compared to cleavage stage biopsy. Furthermore, 
blastocyst stage embryos have a higher implantation potential compared to day-3 or day-4 
embryos, so a higher rate of implantation could be achieved by trophectoderm analysis 
(Kokkali et al., 2007; McArthur et al., 2008). 
2. Materials and methods 
2.1 Study group  
The study group consisted of a total of 188 couples with a total of 362 cycles. Between 2003 
and the mid of 2011 at Istanbul Memorial Hospital, ART and Reproductive Genetics Center, 
149 couples were referred for both mutation analysis for a specific genetic disorder and HLA 
typing, while 39 couples were referred for the sole purpose of HLA typing for acquired 
disorders. The detailed list of diseases can be found in Table 2. 
2.2 Pre-clinical work up 
First, a haplotype analysis of mother, father and child, and when available of other family 
members, was performed for each family prior to preimplantation HLA typing. For this, 
genomic DNA is isolated from peripheral blood samples of father, mother and the affected 
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child. To rule out a possible recombination in the affected child, other family members such 
as unaffected child, or grandparents’ DNA have been added to set up procedure. Figure 1 
shows the polymorphic STR markers scattered through HLA region which were used to 
detect any possible ADO in relation to HLA typing.  
 
 
 
 
         TOTAL 188 couples  362 cycles  
HLA + 
Mutation testing
β-thalassemia  131 258 
Wiscott Aldrich  3 4 
X-Adrenoleukodystrophy  3 3 
Fanconi Anemia  3 4 
Alpha-Mannosidosis  1 4 
Gaucher Syndrome  1 4 
Hurler Syndrome  2 3 
Hyper IgD  1 1 
Glanzmann Trombasthenia  1 2 
Sickle Cell Anemia  1 1 
Diamond Blackfan Anemia  1 1 
Cd3 Deficiency  1 1 
HLA only 
Acute Lymphoblastic Leukemia 17 30 
Acute Myeloid Leukemia  11 20 
Diamond Blackfan Anemia 3 11 
Histiocytosis  1 3 
Chronic Myeloid Leukemia  1 2 
Burkitt’s Lymfoma  1 2 
Aplastic Anemia  2 2 
Anaplastic Anemia  1 3 
Myelodysplastic Syndrome  1 2 
Non-hodgin Lymfoma  1 1 
 
 
Table 2. Cycle participations of patients and indications for HLA Typing. 
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Fig. 1. Polymorphic STR markers used in HLA typing of the embryos. 
A panel of 50 different short tandem repeat (STR) markers (figure 1) were tested on genomic 
DNAs to ensure the presence of enough informative markers (figure 2) to aid the 
identification of monosomy, trisomy, recombination, allele-drop out (ADO) and uniparental 
disomy (UPD) of the analyzed chromosomes and regions. For each family at least 12 
heterozygous markers spanning the HLA-A, HLA-B, HLA-C, HLA-DR,HLA-DQ regions 
(HLA Classes I, II, and III) were selected for PGD Study. 
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Fig. 2. Identification of informative markers during HLA set up study 
The study period was divided into two according to the methods used which included lysis 
of single cells, mutation testing, polymerase chain reaction (PCR) conditions and primers 
used in the PGD study. Oocyte collections, inseminations, culture, biopsy and transfer of 
embryos were performed in Istanbul Memorial Hospital ART unit and all PGD studies and 
evaluations were performed in Istanbul Memorial Hospital Reproductive Genetics Unit. 
2.3 PGD study 
The methods can be found elsewhere (Kahraman et al., 2011). In the first period, the alkaline 
lysis method was used as described previously (Fiorentino et al., 2005). Cells were lysed by 
incubation at 65Cº for 10 minutes in a sterile PCR tube containing 5 µl of lysis buffer 
(200nmol/1 KOH, 50nmol/1 DDT). The lysis buffer was then neutralized prior to adding 
the first-round PCR mix which contained all external primers for co-amplification of all 
selected HLA markers and mutation linked markers. Second-round PCR reaction for each 
locus was then performed using 2 µl of the first round product.  
In the second period, the Proteinase K method was used for lysis of the cells as described 
previously (Verlinsky et al., 2001). The biopsied single cells were placed into a lysis solution 
containing 0,5 µl of 10xPCR buffer, 0,5 µl of 1% tween-20, 0,5 µl of 1% triton X-100, 3,5 µl of 
water, and 0,05 µl of proteinase K. The lysis reaction was as follows: 45 Cº for 15 minutes for 
the lysis of the cells and 96 Cº for 20 minutes for inactivation of proteinase K. Although the 
reaction conditions were different in the two periods, both can be briefly summarized as 
follows; DNA testing was performed by two rounds of PCR reactions: in the first round, 
using multiplex PCR which allows simultaneous amplification of HLA regions and 
mutation-linked markers and in the second round, using singleplex PCR which is a 
fluorescent PCR with semi or heminested primers. Primer sequences and polymerase chain 
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reaction conditions used in this study have been reported previously (Verlinsky et al., 2001; 
Fiorentino et al., 2004; 2005; Rechitsky et al., 2004; Verlinsky et al., 2004). 
Between 2003 and 2008, mutation analysis was performed using the minisequencing 
technique, as described elsewhere (Fiorentino et al., 2003). After middle of 2008 restriction 
enzyme digestion reactions and subsequently polyacrylamide gel electrophoresis analysis 
were used (Rechitsky et al., 2004). Since the middle of 2009s, both methods are being used 
according to preference.  
2.4 IVF and embryo biopsy procedure  
The stimulation protocols were as outlined previously (Kahraman et al., 2004). Oocyte 
retrievals were performed 36 h after the injection of rhCG (ovitrel) by transvaginal-
ultrasound-guidance. Approximately 2-3 h after oocyte retrieval, cumulus cells were 
enzymatically removed. Intracytoplasmic sperm injection (ICSI) was applied to metaphase II 
oocytes. One blastomere was removed from cleavage stage embryos (figure 3a) from an 
opening made using laser (IodoLaser, Research Instruments). Subsequently, embryo transfer  
 
 
a) Clevage Stage Biopsy 
 
 
b) Blastocyst Stage Biopsy 
Fig. 3. Biopsy Techniques 
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was performed usually on day-4 but rarely on day-5. Recently, since 2009, trophectoderm 
tissue biopsies have also been performed. Blastocyst-stage biopsy was performed by making 
a hole in the zona pellucida on day-3 of embryonic development which allowed the 
developing trophectoderm cells to protrude after blastulation, facilitating the biopsy. On 
day-5 post-fertilization, approximately 4-5 cells were excised using laser energy, without 
loss of inner cell mass (figure 3b). After diagnosis, the embryos was replaced during the 
same cycle, on day-5 or 6. Pregnancy was first evaluated by serum hCG concentrations 
assay, 12 days after embryo transfer and clinical pregnancy was diagnosed by 
ultrasonographic visualization of one or more gestational sacs. 
3. Results  
In HLA+mutation testing group (Group I), and HLA-only group (Group II), 62.2% and 
72.4% of the initiated cycles reached the stage of embryo transfer, respectively. The detailed 
distribution of indications and overall results for each group was shown in Table 2 and 3. 
A full diagnosis was achieved in 91.0% of the biopsied samples. In Group I, 17.8 % of the 
analyzed embryos were found to be HLA compatible. HLA compatible and disease free 
embryos were 12.9 % of all diagnosed embryos. In group II, 17.2% of embryos were found to 
be HLA matched and 71.4% HLA non-matched. 
 
 
HLA+mutation 
testing 
(Group I) 
HLA Only 
(Group II) 
TOTAL 
No of patients/cycles  149/286  39/76  188/362 
Maternal age, mean 32.0±4.83  33.9±5.65 
Cycles with transfer, %  62.2  72.4  
No of embryos transfered, mean  1.55±0.71  1.56±0.72  
Clinical pregnancy rate per transfer, %  37.6  32.7  
Implantation rate,%  28.9  24.4  
Clinical miscarriages,  n  14  3  
No of babies born, n  57  13  
No of succsessful transplantations, n  23  2  25*  
* 21 children are awaiting an appropriate time for HSC transplantation. 
Table 3. Overall clinical results of HLA typing. 
The majority of our HLA typing combined with PGD cases were β-Thalassemia carriers 
(87.9%). The mutations analyzed have high heterogeneity, the most frequent mutation was 
IVS-I-110 G-A and comprised 46.2% of all mutations. The total frequency of the most 
frequent 6 mutations were 74.0% (Table 4). 
A total of 85 clinical pregnancies (36.5%) were achieved from 233 ET cycles. 5 pregnancies 
are ongoing. To date, 70 healthy and HLA compatible children have been born. 25 sick 
children have already been cured with cord blood cell and/or bone marrow transplantation. 
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21 children are waiting for their newborn siblings to gain sufficient weight and maturity for 
the donation of stem cells (Table 3). The successful transplantations have been performed for 
the following indications: β-Thalassemia (n=19), Wiskott Aldrich syndrome (n=2), 
Glanzmann Disease (n=1), X-Adrenoleukodystrophy (n=1) and acute myeloid leukemia 
(n=1) and Diamond Blackfan anemia (n=1) (Table 5).  
 
Mutation Frequency , % 
IVS-I-110 G-A 46.2 
Cod8 delAA 7.3 
Cod39 C-T 6.5 
IVS-II-745 5.7 
IVS-II-1 4.6 
IVS-I-1 G-A 3.8 
TOTAL 74.0 
Table 4. The most frequent Beta-Thalassemia mutations in our sample population 
4. Conclusion  
This data presents one of the world’s largest experiences on preimplantation HLA typing, 
and the outcome of stem cell transplantation is the largest number available from one center. 
To date 25 children have been cured with this approach and 21 children are awaiting 
appropriate time for transplantation. Our results indicate HLA typing with or without 
mutation analysis is a promising and effective therapeutic tool for curation of an affected 
sibling. 
 
Indication Patients, n 
Beta-Thalassemia 19 
Wiscott-Aldrich 2 
Glanzmann disease 1 
X-Adrenoleukodystrophy 1 
Acute Myeloid Leukemia 1 
Diamond Blackfan Anemia 1 
TOTAL 25 
 
Table 5. The list of diseases and the number of patients who have complete cure after HSCT. 
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